We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

AHA Updates Treatment Guidelines for Atrial Fibrillation

By HospiMedica International staff writers
Posted on 04 Feb 2019
Image: New research shows NOACs are preferred over warfarin as an anticoagulant in AF (Photo courtesy of 123RF).
Image: New research shows NOACs are preferred over warfarin as an anticoagulant in AF (Photo courtesy of 123RF).
The American Heart Association (AHA; Dallas, TX, USA), American College of Cardiology (ACC; Washington, DC, USA), and the Heart Rhythm Society (HRS; Washington, DC, USA) now recommend the use of non-vitamin K oral anticoagulants (NOACs) over traditional warfarin to prevent stroke in people with atrial fibrillation (AF).

The recommendations are the result of a focused update to the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. The new guideline also suggests that NOACs could even be used in people at a lower risk of stroke than previously thought, with emerging research suggesting the benefit of NOACs in stroke reduction risk outweighs the risk of taking them. The recommendation was simultaneously published on January 29, 2019, in Circulation, the Journal of the American College of Cardiology (JACC), and HeartRhythm.

“Patients with atrial fibrillation are at increased risk of stroke, which can be devastating. A goal of treating AF patients is to make blood less likely to form clots, which reduces the risk of stroke,” said Craig T. January, MD, PhD, co-chair of the updated guideline committee. “NOACs may be safer for patients because there is less risk of bleeding, and they may also be more effective at preventing blood clots than warfarin. AF patients should talk to their healthcare provider about any concerns they have about their prescribed medications and whether or not losing weight would benefit their health.”

Until the introduction of NOACs, warfarin had been one of the only treatment options for long-term anticoagulation of patients with AF, venous thromboembolism (VTE), or other conditions that require chronic anticoagulation. The major benefit of the NOAC anticoagulants is that they do not require strict and frequent laboratory monitoring, dosing adjustments, or dietary restrictions, and incur fewer drug interactions than warfarin. NOACs include dabigatran, rivaroxaban, apixaban, and edoxaban.

Related Links:
American Heart Association
American College of Cardiology
Heart Rhythm Society

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
MR Trolley
MR9002
New
Measuring Rod
seca 233

Channels

Surgical Techniques

view channel
Image: For the first time, a fluorescent-guided nerve imaging agent has shown promise for use in humans (Photo courtesy of VUMC)

Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery

Surgical nerve injury is a significant concern in head and neck surgeries, where nerves are at risk of being inadvertently damaged during procedures. Such injuries can lead to complications that may impact... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more